MannKind shares drop 18% after FDA says it will pass on new blood pressure drug
Shares of Westlake Village-based MannKind Corp. dropped 18% on Oct. 18, after the U.S. Food and Drug Administration did not approve a hypertension treatment the company is developing with United Therapeutics. In a complete letter response, the FDA declined to approve a new drug application for Tyvasio DPI, a treatment being developed by MannKind and Read More →
Read More →
Amgen’s investment in Neumora marks a return to neuroscience research
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen goes full speed ahead on biosimilar drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen invests $100M in startup pursuing brain treatments
An Amgen-funded biotech company launched Oct. 7, announcing a strategic partnership between the two companies that includes $100 million in funding and global rights to develop and sell some of Amgen’s experimental drugs for neurodegenerative diseases. Thousand Oaks-based Amgen, one of the largest biotech companies in the world, committed $100 million in equity investment to Read More →
Read More →Amgen wins patent case
Thousand Oaks-based Amgen had a big win in court on Sept. 20, as a federal court in New Jersey upheld multiple Amgen patents for its psoriasis treatment, Otezla. Amgen filed a patent infringement lawsuit earlier this year against two companies, Sandoz and Zydus Pharmaceuticals, claiming that their generic versions of Otezla infringed upon at least Read More →
Read More →Arcutis starts new Phase 3 trial
Arcutis Biotherapeutics announced Aug. 25 that it has enrolled the first patient in a Phase 3 clinical trial to evaluate ARQ-154, its topical foam, as a treatment for scalp and body psoriasis. The foam is a once-daily formulation of roflumilast, a phosphodiesterase type 4 inhibitor that the company is developing to treat two skin conditions: Read More →
Read More →Revenue and losses both growing at MannKind
MannKind saw a significant rise in revenue thanks to its product Afrezza, but its net loss in the second quarter of fiscal year 2021 also rose significantly as the company tried to pay down its debt. The Westlake Village biotech company released its earnings after the markets closed on Aug. 11. It opened the next Read More →
Read More →
SPONSORED CONTENT:
